The full pipeline watchlist at a glance — peak sales, stage / PDUFA dates and stakeholder coverage.
Tracking launch brands offers one of the biggest opportunities to smash your targets out of the ballpark. Staying on top of new drugs coming through the pipeline gives you a real advantage when trying to land major deals.
This article highlights 10 drugs worth watching based on their projected commercial potential, recent clinical or regulatory momentum, and the stakeholder coverage developing around each brand.
The 10 in detail
Retatrutide
Lilly
Lilly's triple-agonist retatrutide is one of the biggest metabolic assets to watch, with projected peak future sales of $15.0B. Strong Phase 3 results across Type 2 diabetes and obesity, including major weight loss data, position it as a potential successor to Zepbound and a serious competitor to Novo Nordisk's obesity franchise.
Daraxonrasib
RevMed
RevMed's daraxonrasib is one of the most commercially significant oncology assets on our watchlist, with projected peak future sales of $7.6B. The pan-RAS inhibitor is being developed across lung cancer and pancreatic cancer, and met the primary endpoint in Phase 3 metastatic pancreatic cancer, nearly doubling median overall survival to 13.2 months. The company now plans to submit the data to global regulators.
CagriSema
Novo Nordisk
Novo Nordisk's CagriSema remains a key obesity asset to watch, despite mixed competitive headlines. The fixed-dose combination of cagrilintide and semaglutide has been submitted to the FDA for chronic weight management, with a regulatory decision expected in October 2026. Phase 3 data showed around 22.7% weight loss, while a head-to-head trial against Zepbound has pushed Novo to explore a high-dose study.
Survodutide
Boehringer Ingelheim
Boehringer Ingelheim's survodutide is being developed across obesity and MASH, giving it relevance in two highly active metabolic markets. The dual agonist achieved 16.6% average weight loss in a Phase 3 obesity trial, with the study meeting its primary endpoint. With projected peak future sales of $6.4B, it is one of Boehringer's most important late-stage pipeline assets.
Bezuclastinib
Cogent
Cogent's bezuclastinib is a high-value oncology asset with projected peak future sales of $5.7B. The FDA has accepted its NDA for non-advanced systemic mastocytosis, with a December 2026 PDUFA date. The drug has also delivered positive Phase 3 data in GIST, including a 46% objective response rate and 16.5 months median progression-free survival when combined with sunitinib.
Baxdrostat
AstraZeneca
AstraZeneca's baxdrostat is a major cardiovascular asset for treatment-resistant hypertension, with projected peak future sales of $5.0B. New Phase 3 data showed a 14 mmHg placebo-adjusted reduction in 24-hour average systolic blood pressure over 12 weeks, strengthening its position as a potential new option for uncontrolled hypertension. The drug has a June 2026 PDUFA date.
Ianalumab
Novartis
Novartis' ianalumab is a late-stage immunology and rare disease asset with projected peak future sales of $5.0B. The FDA granted breakthrough therapy designation for Sjögren's disease based on positive Phase 3 data. Its multi-indication potential across ITP and Sjögren's disease makes it one to watch closely.
Povetacicept
Vertex
Vertex's povetacicept is a rare disease asset being developed in IgAN, with projected peak future sales of $4.0B. The BLA was submitted in March 2026 with a Priority Review Voucher, following Phase 3 interim data showing a 49.8% reduction in proteinuria. An FDA decision is expected in H2 2026.
Azetukalner
Xenon
Xenon's azetukalner is a Phase 3 neurology asset in epilepsy, with projected peak future sales of $2.5B. The drug met its primary endpoint in focal onset seizures, with the 25 mg dose reducing seizure frequency by 53.2% compared to placebo. Xenon plans to submit an NDA to the FDA in Q3 2026, making this an important specialist-market launch to track.
Iberdomide
BMS
BMS' iberdomide is a hematology oncology asset in relapsed or refractory multiple myeloma, with projected peak future sales of $1.3B. The FDA granted Priority Review for iberdomide in combination with daratumumab and dexamethasone, with a target action date in August 2026. Alongside mezigdomide, it forms part of BMS' broader CELMoD strategy, which is becoming an important area of commercial build-out.
These assets span some of the most active areas of pharma development, from obesity and oncology to rare disease, cardiovascular, neurology, immunology, and hematology.
While not every late-stage asset becomes a major launch, each of these drugs has signals that make it worth tracking: meaningful commercial potential, clinical or regulatory momentum, and stakeholder activity already forming around the brand.
Interested in monthly pipeline news updates and the contacts behind the brands?